MicroPort

Home
China
Shanghai
MicroPort

MicroPort is all about improving human life through the practical application of innovative science.

06/11/2025

As comes to a close, we extend our heartfelt thanks to everyone who made this year’s event a remarkable success.

From the release of the TARGET SAFE clinical study results, to inspiring discussions with global experts at TCTMD and booth interviews, this year's TCT truly reflected our spirit of Pushing Boundaries, Beyond Borders.

Thank you to all our partners, KOLs, and colleagues for your dedication, collaboration, and passion for advancing cardiovascular innovation.

We look forward to seeing you again at ! 💙

26/08/2025

On August 25, received official approval from the National Medical Products Administration (NMPA) for the FireGuard™EXT in China.

The FireGuard™EXT was developed to address the evolving needs of interventional cardiologists in . By providing enhanced backup support at the coronary ostium and enabling smooth device delivery into distal lesions without deep intubation, FireGuard™EXT serves as an indispensable adjunct to guiding catheters in both coronary and peripheral interventions.

Guide extension catheters have become a critical tool in PCI, especially in complex scenarios such as . Whether physicians employ antegrade wire escalation or advanced re-entry techniques, the device delivers reliable procedural support with proven clinical value.

FireGuard™EXT integrates multiple advanced design features:
1️⃣ Enlarged inner lumen (0.058" at 6Fr): Facilitates smooth passage of devices through tortuous anatomies while ensuring sufficient support.
2️⃣ Reinforced structural stability: Proprietary integrated welding and polymer rheology technology enhance durability and reduce risks of deformation or fracture, ensuring procedural safety.
3️⃣ Optimized 5cm half-pipe rail: Achieves the balance between crossing performance and device deliverability.
4️⃣ Braided shaft design: Provides superior pushability and consistent backup support for complex interventions.

29/07/2025

® announced the successful first implantation of its ® Left Atrial Appendage Closure System in Hong Kong, China in July. The groundbreaking procedure was performed at Canossa Hospital - Hong Kong Asia Heart Centre, marking a significant milestone in the adoption of next-generation technology in the region.

The AnchorMan® LAAC system was used to significantly reduce the risk of stroke in a patient with atrial fibrillation by sealing off the left atrial appendage, demonstrating exceptional device performance and procedural success. At Canossa Hospital - Hong Kong Asia Heart Centre, the procedure was led by Professor LAM Yat Yin and Dr. Ivan WONG Man Ho, who successfully implanted the device in an elderly patient using a minimally invasive approach. The patient exhibited rapid postoperative recovery with no complications, underscoring the efficacy of the system.

We are honored to collaborate with Canossa Hospital - Hong Kong Asia Heart Centre and distinguished key opinion leaders from China to introduce the AnchorMan® system. These landmark procedures reinforce our commitment to providing cutting-edge cardiovascular solutions that improve patient outcomes and quality of life.

We would like to extend our appreciation to the clinical teams for their exceptional skill and commitment to advancing structural heart disease treatment.

28/07/2025

announced the successful completion of the first five implants of its next-generation Liberty® Transcatheter Aortic Valve Implantation (TAVI) system in Brazil in July, mark a significant advancement in accessible, innovative structural heart therapies for Brazilian patients.
The milestone implants were led by a distinguished team of Brazilian physicians: Dr. José Mariani Jr, Dr. Guy Prado, Dr. Pedro Nicz, Dr. Ricardo Ghetti, Dr. Edgard Quintella, Dr. Eduardo Pessoa de Melo, and Dr. Pedro Lemos

With Dr. Matías Sztejfman serving as the Lead Proctor, the cases demonstrated the system's exceptional clinical performance—including rapid postoperative recovery via minimally invasive approaches and successful management of complex anatomies—validating its precision and adaptability.
The procedures leveraged a strategic partnership between the technical teams of Albert Einstein Israelite Hospital (Einstein) and Santa Casa de Misericórdia de São Paulo in hemodynamic cardiology.

We would like to extend deepest appreciation to the Brazilian physician team for their exceptional skill and dedication and to the Lead Proctor Dr. Matías Sztejfman, for his indispensable expertise and commitment to knowledge transfer.

06/03/2025

is proud to announce that AnchorMan®- Left Atrial Appendage Closure ( ) device, officially received CE MDR certification. This achievement underscores our commitment to advancing medical technology and improving patient care globally.

1️⃣ Unique 12 “3D folding” units at distal, forming a semi-closed structure with a mesh frame, addressing clinical challenges faced by traditional devices that require depth of left atrial appendage.
2️⃣ Round and flexible distal end, reducing potential damage to the tissue, ensuring a more secure and stable anchoring.
3️⃣ The dense nitinol frame is designed to better adapt to the shape of the LAA, improving the sealing effect.
4️⃣ Offering both “ Unsheathe” and “Advanced” release mode, for the physician during the procedure, ensuring optimal placement.

Address

No. 1601 Zhangdong Road
Shanghai
210203

Telephone

86-21-38954600

Website

http://www.microport.com/

Alerts

Be the first to know and let us send you an email when MicroPort posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to MicroPort:

Shortcuts

Want your practice to be the top-listed Clinic in Shanghai?